Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
The Royal College Of Surgeons In Ireland has 5 pending office actions currently active within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, ensuring that no two pending matters are being reviewed by the same person. This distribution suggests a decentralized prosecution process where each application is subject to the unique interpretation and requirements of a different examiner. The portfolio's activity is further dispersed across 5 distinct art units, matching the total count of pending office actions and examiners.
SPENCE, JENNIFER SUZANNE is the busiest examiner for the portfolio, yet she is responsible for only 1 busiest examiner pending action. This confirms that the workload is evenly spread, with each of the 5 distinct examiners managing exactly one action. This alignment indicates that each of the 5 pending office actions is likely situated in a different technical niche within the broader Biotechnology & Pharmaceuticals field. For the practitioner, this high level of dispersion means that prosecution strategies must be individually tailored for each application, as there is no examiner-level or art unit-level concentration to allow for a unified approach across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| XU, JUSTIN | 1 | 60.2% | +36.7% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| ANGELL, JON E | 1 | 71.0% | +21.1% |
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018819 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES BY ENHANCING ARGINASE 2 IN MACROPHAGES | ANGELL, JON E | 84d |
| 18572106 | METHOD AND SYSTEM TO QUANTIFY AND PREDICT CHANGES IN LUNG FUNCTION | XU, JUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018819 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES BY ENHANCING ARGINASE 2 IN MACROPHAGES | ANGELL, JON E | 84d |
| 19035397 | A METHOD FOR INHIBITING BINDING OR CROSS-LINKING TO VASCULAR ENDOTHELIAL CELLS | SPENCE, JENNIFER SUZANNE | — |
| 18572106 | METHOD AND SYSTEM TO QUANTIFY AND PREDICT CHANGES IN LUNG FUNCTION | XU, JUSTIN | — |
| 18262299 | TREATMENT OF CORONAVIRUS | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17828969 | USE OF FKBP-L POLYPEPTIDES AND NUCLEIC ACIDS FOR THE TREATMENT OF OBESITY | MARTINEZ, TARA L | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 3791 | 1 |
| 1658 | 1 |
| 1637 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19035397 | A METHOD FOR INHIBITING BINDING OR CROSS-LINKING TO VASCULAR ENDOTHELIAL CELLS | SPENCE, JENNIFER SUZANNE | 1633 | §102 | Non-Final OA | — | Pending | Jan 23, 2025 |
| 18572106 | METHOD AND SYSTEM TO QUANTIFY AND PREDICT CHANGES IN LUNG FUNCTION | XU, JUSTIN | 3791 | §101 | Final Rejection | — | Pending | Dec 19, 2023 |
| 18262299 | TREATMENT OF CORONAVIRUS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112DPOther | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18018819 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES BY ENHANCING ARGINASE 2 IN MACROPHAGES | ANGELL, JON E | 1637 | §102§112 | Non-Final OA | 84d | Pending | Jan 30, 2023 |
| 17828969 | USE OF FKBP-L POLYPEPTIDES AND NUCLEIC ACIDS FOR THE TREATMENT OF OBESITY | MARTINEZ, TARA L | 1654 | §103 | Non-Final OA | — | Pending | May 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial